Idera Pharmaceuticals, Inc. IDRA today announced that it has
entered into a Materials Cooperative Research and Development Agreement
(M-CRADA) with the National Cancer Institute (NCI) to evaluate the
Company's Toll-like receptor (TLR) antagonists as a potential approach
to the treatment of certain genetically defined B-cell lymphomas.
"We are pleased to have entered into this agreement, and we look forward
to communicating further on it as the work underway proceeds," said
Sudhir Agrawal, D. Phil., Chief Executive Officer of Idera
Pharmaceuticals.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals technology platform involves creating novel
synthetic RNA- and DNA-based compounds to modulate immune responses.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in